TRIP13

Across TCGA pan-cancer cohorts, TRIP13 RNA is linked to patient survival in 30 of 34 cancer types, making it the most broadly survival-associated TRIP13 data layer compared with 6 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher TRIP13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIP13 expression acts as an unfavorable survival marker, although some lineages such as UCS and READ show a favorable association.

KIRP, ACC, and MESO are the cancer types where TRIP13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.757	0.946	<.001	168	view →
ACC	DFS	Median	All	0.164	0.709	<.001	161	view →
MESO	OS	Median	All	0.369	0.710	<.001	123	view →
KICH	DFS	Quartile	All	0.477	0.954	<.001	105	view →
KIRC	DFS	Median	All	0.545	0.705	<.001	102	view →
LIHC	DFS	Median	All	0.447	0.636	<.001	85	view →
LGG	OS	Median	All	0.729	0.887	<.001	52	view →
THCA	DFS	Quartile	All	0.698	0.914	<.001	42	view →
UCS	DFS	Quartile	III,IV	0.659	0.119	.003	40	view →
UCEC	OS	Quartile	All	0.801	0.926	<.001	36	view →
BRCA	DFS	Tertile	IV	0.360	0.837	.006	34	view →
LUAD	OS	Median	All	0.760	0.860	<.001	33	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 30 lineages.

TRIP13–KIRP (DFS)

Open the KIRP breakdown →